FGI-106-tetrahydrochloride-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEFGI-106tetrahydrochlorideCat.No.:HY-124618ACASNo.:1149348-10-6分?式:C??H??Cl?N?分?量:604.49作?靶點(diǎn):InfluenzaVirus;HCV;HIV作?通路:Anti-infection儲(chǔ)存?式:4°C,sealedstorage,awayfrommoisture*Insolvent:-80°C,6months;-20°C,1month(sealed

storage,awayfrommoisture)溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:6.67mg/mL(11.03mM;ultrasonicandwarmingandadjustpHto2withHClandheatto60°C)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM1.6543mL8.2714mL16.5429mL5mM0.3309mL1.6543mL3.3086mL10mM0.1654mL0.8271mL1.6543mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month(sealedstorage,awayfrommoisture)。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥0.67mg/mL(1.11mM);Clearsolution2.請(qǐng)依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥0.67mg/mL(1.11mM);Clearsolution1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEBIOLOGICALACTIVITY?物活性FGI-106tetrahydrochloride?種有效的?譜抑制劑，對(duì)多種病毒具有抑制活性。FGI-106tetrahydrochloride具有抗埃博拉病毒(EBOV)，裂?病毒(RiftValleyvirus)和登?熱病毒(DengueFevervirus)的活性，其EC50分別為100nM，800nM和400-900nM。FGI-106tetrahydrochloride還分別以EC50值為200nM和150nM抑制?失?性發(fā)熱病毒HCV和HIV-1。IC50&TargetEC50:100nM(Ebolavirus),800nM(RiftValleyvirus),400-900nM(DengueFevervirus),200nM(HCV)and150nM(HIV-1)[1]體外研究Treatmentwith2μMFGI-106mediateda4logreductionininfectiousviraltitersrelativetomatchedcontrols,withanEC90forinhibitionofviralkillingofhostcells(VeroE6cells)estimatedtobe0.6μM[1].Incell-basedassays,treatmentwithFGI-106inhibitsviralreplicationbydivergentvirusfamilies,includingpositiveandnegative-strandRNAviruses[1].體內(nèi)研究FGI-106(0.1-5mg/kg;intraperitonealinjection;treatmentsondays2and5;C57BL/6orBALB/cmice)treatmentdecreasesmortalityfromZaireEBOVinadose-dependentmanner[1].AnimalModel:MaleorfemaleC57BL/6orBALB/cmice(6-10weeksofage)injectedwithEBOV(Ebolavirus)[1]Dosage:0.1mg/kg,0.5mg/kg,1mg/kg,2mg/kg,5mg/kgAdministration:Intraperitonealinjection;treatmentsondays2and5Result:DecreasedmortalityfromZaireEBOVinadose-dependentmanner.REFERENCES[1].AmanMJ,etal.Developmentofabroad-spectrumantiviralwithactivityagainstEbolavirus.AntiviralRes.2009Sep;83(3):245-51.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplica